Catalyst Health Ventures

Catalyst Health Ventures (CHV) is a Boston-based venture capital firm founded in 2000, exclusively focused on innovative early-stage MedTech companies. With over two decades dedicated to the healthcare sector, the firm invests in visionary teams developing breakthrough medical technologies that address significant global unmet clinical needs. The team comprises 13 members including three partners and one venture partner, operating from its office at 129 South Street in Boston. CHV leads rounds at the Seed and Series A stages, writing checks of $1 million to $5 million with continued participation in follow-on rounds through exit. Across 80 investments, the firm has recorded 12 portfolio exits — including acquisitions by Boston Scientific, Veracyte, Agilent Technologies, Life Technologies, and W.L. Gore & Associates, as well as Sera Prognostics' NASDAQ IPO. Key focus areas include oncology, cardiovascular disease, obesity, and women's health, spanning therapeutic devices, diagnostics, drug delivery, and digital health. Recent investments include Conformal Medical, Esperto Medical, Venova Medical, and Aria CV. CHV brings strategic insight, deep industry expertise, and a hands-on collaborative approach to every portfolio relationship. The firm's particular strength lies in helping founders navigate the distinctive regulatory and commercialization complexities of the medical device and diagnostics landscape — a path that requires far more than capital. That specialization, sustained consistently over 25 years, has made Catalyst Health Ventures one of the most experienced dedicated MedTech investors in the United States.